1. Home
  2. MBIO vs SXTP Comparison

MBIO vs SXTP Comparison

Compare MBIO & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MBIO

Mustang Bio Inc.

HOLD

Current Price

$0.51

Market Cap

4.1M

Sector

Health Care

ML Signal

HOLD

Logo 60 Degrees Pharmaceuticals Inc.

SXTP

60 Degrees Pharmaceuticals Inc.

HOLD

Current Price

$0.92

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBIO
SXTP
Founded
2015
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1M
3.6M
IPO Year
2023
2023

Fundamental Metrics

Financial Performance
Metric
MBIO
SXTP
Price
$0.51
$0.92
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$14.10
AVG Volume (30 Days)
19.4K
47.6K
Earning Date
05-13-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
98.99
36.77
EPS
N/A
N/A
Revenue
N/A
$1,005,471.00
Revenue This Year
N/A
$33.92
Revenue Next Year
N/A
$51.35
P/E Ratio
N/A
N/A
Revenue Growth
N/A
65.49
52 Week Low
$0.52
$0.34
52 Week High
$1.84
$8.62

Technical Indicators

Market Signals
Indicator
MBIO
SXTP
Relative Strength Index (RSI) 35.11 33.56
Support Level N/A $0.45
Resistance Level $0.66 $1.12
Average True Range (ATR) 0.02 0.09
MACD -0.00 -0.00
Stochastic Oscillator 0.00 12.65

Price Performance

Historical Comparison
MBIO
SXTP

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

About SXTP 60 Degrees Pharmaceuticals Inc.

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.

Share on Social Networks: